BeiGene, Ltd. (NASDAQ:BGNE) Receives $246.21 Consensus PT from Analysts

BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $246.21.

Several research firms recently commented on BGNE. Citigroup increased their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. JMP Securities began coverage on BeiGene in a report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 target price for the company. Bank of America dropped their price target on shares of BeiGene from $180.00 to $152.50 and set a "neutral" rating on the stock in a research report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 22nd.

BeiGene Price Performance

BGNE traded up $0.78 on Tuesday, reaching $208.03. The company had a trading volume of 283,463 shares, compared to its average volume of 263,694. The company has a market capitalization of $20.25 billion, a P/E ratio of -40.83 and a beta of 0.63. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $211.76 and a 200-day moving average of $178.98. BeiGene has a one year low of $126.97 and a one year high of $248.16.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) EPS for the quarter, beating analysts' consensus estimates of ($2.27) by $1.12. The business had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business's revenue for the quarter was up 56.1% on a year-over-year basis. During the same quarter last year, the business earned ($3.64) earnings per share. As a group, equities research analysts anticipate that BeiGene will post -5 earnings per share for the current year.

Insider Activity

In other news, CEO John Oyler sold 6,175 shares of the business's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,070 shares of company stock worth $4,901,050. 7.43% of the stock is currently owned by corporate insiders.

Institutional Trading of BeiGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. increased its position in BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after buying an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in BeiGene in the 3rd quarter valued at $36,000. Headlands Technologies LLC acquired a new stake in BeiGene during the 1st quarter valued at $50,000. SG Americas Securities LLC bought a new position in BeiGene during the third quarter worth $105,000. Finally, PFG Investments LLC bought a new position in shares of BeiGene in the third quarter valued at about $210,000. Institutional investors own 48.55% of the company's stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.